Conditions: Purpura, Thrombocytopenic, Idiopathic
Keywords: Adult Refractory Immune Thrombocytopenic Purpura (ITP)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).

Detailed description:
Patients with chronic refractory ITP are eligible for a 6- to 12-week therapeutic trial. After 24 months of treatment, patients who continue to demonstrate a sustained response, in the investigator's judgment, will be offered the opportunity to receive ongoing therapy.

Arms:
arm 1: None

Interventions: intervention 1: Fostamatinib Disodium / R935788
Intervention descriptions: intervention 1: R935788 tablets

Protocol document: